A Novel Serotonin Blocker, Sarpogrelate, Increases Circulating Adiponectin Levels in Diabetic Patients With Arteriosclerosis Obliterans
- Jun’ichi Yamakawa, MD,
- Takashi Takahashi, MD,
- Tohoru Itoh, MD,
- Kazuya Kusaka, MD,
- Ken Kawaura, MD,
- Xin Qui Wang, MD and
- Tsugiyasu Kanda, MD
- From the Department of General Medicine, Kanazawa Medical University, Ishikawa, Japan
- Address correspondence to Dr. Tsugiyasu Kanda, Department of General Medicine, Kanazawa Medical University, 1-1, Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa, 920-0293, Japan. E-mail: kandat{at}kanazawa-med.u.ac.jp
The recent article by Tsunekawa et al. (1) demonstrates that adiponectin plays an important role in improving insulin resistance. Inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6), are associated with the risk of development of arteriosclerosis among both diabetic and nondiabetic patients (2).
Low plasma adiponectin concentrations were clinically observed in patients with type 2 diabetes (3). These findings suggest that adiponectin might have anti-inflammatory properties and might act as an endogenous modulator for the development of obesity-related diseases.
Serotonin is a naturally occurring vasoactive substance and has also been involved with vascular inflammation leading to the atherosclerosis (4). Sarpogrelate hydrochloride is a serotonin 2A receptor antagonist and is clinically used for the cutaneous ulcer and ischemic change resulting from the arteriosclerosis.
Cryesthesia was defined …
